{"id":1488,"date":"2026-09-07T16:16:46","date_gmt":"2026-09-07T14:16:46","guid":{"rendered":"https:\/\/amyloidosisalliance.local\/essais-cliniques\/"},"modified":"2026-09-29T11:06:38","modified_gmt":"2026-09-29T09:06:38","slug":"essais-cliniques","status":"publish","type":"page","link":"https:\/\/www.amyloidosisalliance.org\/fr\/essais-cliniques\/","title":{"rendered":"Essais cliniques"},"content":{"rendered":"\n<nav aria-label=\"Breadcrumb\" class=\"wp-block-group aa-breadcrumb is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"aa-inner\"><a href=\"https:\/\/www.amyloidosisalliance.org\/fr\/\">Accueil<\/a><span class=\"aa-breadcrumb__sep\">\u203a<\/span><span class=\"aa-breadcrumb__current\">Essais cliniques<\/span><\/div>\n<\/nav>\n\n<section class=\"wp-block-group aa-page-hero is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group aa-inner is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group aa-page-hero__grid is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group is-layout-flow wp-block-group-is-layout-flow\">\n<p class=\"aa-overline wp-block-paragraph\">Recherche<\/p>\n\n\n\n<h1 class=\"wp-block-heading\">Essais cliniques<\/h1>\n\n\n\n<p class=\"aa-lead wp-block-paragraph\">Toutes les \u00e9tudes sur l\u2019amylose qui recrutent, vont ouvrir ou recrutent sur invitation, partout dans le monde, directement issues de ClinicalTrials.gov et mises \u00e0 jour chaque jour.<\/p>\n\n\n\n<p class=\"aa-trial-warn wp-block-paragraph\"><strong>Une information, pas un avis m\u00e9dical.<\/strong> L\u2019Alliance ne conduit pas ces \u00e9tudes et ne peut pas vous y inscrire. Si un essai vous semble pertinent, parlez-en au m\u00e9decin qui suit votre amylose.<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-group aa-page-hero__photo is-layout-flow wp-block-group-is-layout-flow\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1707\" height=\"1707\" src=\"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766.jpg\" alt=\"\" class=\"wp-image-1000\" srcset=\"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766.jpg 1707w, https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766-300x300.jpg 300w, https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766-1024x1024.jpg 1024w, https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766-150x150.jpg 150w, https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766-768x768.jpg 768w, https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766-1536x1536.jpg 1536w\" sizes=\"auto, (max-width: 1707px) 100vw, 1707px\" \/><\/figure>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n\n<section id=\"trials\" class=\"wp-block-group aa-section aa-section--cream aa-trials-page is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group aa-inner is-layout-flow wp-block-group-is-layout-flow\">\n<h2 class=\"wp-block-heading\">\u00c9tudes en cours de recrutement et \u00e0 venir<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">La liste couvre les amyloses AL, ATTR et AA ainsi que l\u2019angiopathie amylo\u00efde c\u00e9r\u00e9brale. Chaque fiche indique o\u00f9 en est l\u2019\u00e9tude\u00a0: ouverte \u00e0 toute personne qui remplit ses crit\u00e8res, pas encore ouverte, ou r\u00e9serv\u00e9e aux personnes invit\u00e9es par les investigateurs. Les \u00e9tudes qui se terminent disparaissent simplement de la liste.<\/p>\n\n\n<div class=\"aa-trials aa-no-reveal wp-block-aa-clinical-trials\" data-endpoint=\"https:\/\/www.amyloidosisalliance.org\/fr\/wp-json\/aa\/v1\/trials\" data-page=\"0\" data-per-page=\"12\"><form class=\"aa-trial-filters\" method=\"get\" action=\"https:\/\/www.amyloidosisalliance.org\/fr\/\"><p class=\"aa-trial-filters__field\"><label class=\"aa-trial-filters__label\" for=\"aa-trial-t_type\">Type d&#039;amylose<\/label><select class=\"aa-trial-filters__select\" id=\"aa-trial-t_type\" name=\"t_type\"><option value=\"\">Tous les types<\/option><option value=\"attr\">ATTR (transthyr\u00e9tine)<\/option><option value=\"al\">AL (cha\u00eenes l\u00e9g\u00e8res)<\/option><option value=\"aa\">AA (secondaire)<\/option><option value=\"caa\">Angiopathie amylo\u00efde c\u00e9r\u00e9brale<\/option><option value=\"unspecified\">Non pr\u00e9cis\u00e9<\/option><\/select><\/p><p class=\"aa-trial-filters__field\"><label class=\"aa-trial-filters__label\" for=\"aa-trial-t_country\">Pays<\/label><select class=\"aa-trial-filters__select\" id=\"aa-trial-t_country\" name=\"t_country\"><option value=\"\">Tous les pays<\/option><option value=\"Argentina\">Argentina<\/option><option value=\"Australia\">Australia<\/option><option value=\"Austria\">Austria<\/option><option value=\"Belgium\">Belgium<\/option><option value=\"Brazil\">Brazil<\/option><option value=\"Bulgaria\">Bulgaria<\/option><option value=\"Canada\">Canada<\/option><option value=\"Chile\">Chile<\/option><option value=\"China\">China<\/option><option value=\"Croatia\">Croatia<\/option><option value=\"Cyprus\">Cyprus<\/option><option value=\"Czechia\">Czechia<\/option><option value=\"Denmark\">Denmark<\/option><option value=\"Estonia\">Estonia<\/option><option value=\"Finland\">Finland<\/option><option value=\"France\">France<\/option><option value=\"Germany\">Germany<\/option><option value=\"Greece\">Greece<\/option><option value=\"Hong Kong\">Hong Kong<\/option><option value=\"Hungary\">Hungary<\/option><option value=\"Ireland\">Ireland<\/option><option value=\"Israel\">Israel<\/option><option value=\"Italy\">Italy<\/option><option value=\"Japan\">Japan<\/option><option value=\"Latvia\">Latvia<\/option><option value=\"Lithuania\">Lithuania<\/option><option value=\"Malaysia\">Malaysia<\/option><option value=\"Martinique\">Martinique<\/option><option value=\"Mexico\">Mexico<\/option><option value=\"Netherlands\">Netherlands<\/option><option value=\"New Zealand\">New Zealand<\/option><option value=\"Norway\">Norway<\/option><option value=\"Poland\">Poland<\/option><option value=\"Portugal\">Portugal<\/option><option value=\"Romania\">Romania<\/option><option value=\"Singapore\">Singapore<\/option><option value=\"Slovakia\">Slovakia<\/option><option value=\"Slovenia\">Slovenia<\/option><option value=\"South Korea\">South Korea<\/option><option value=\"Spain\">Spain<\/option><option value=\"Sweden\">Sweden<\/option><option value=\"Switzerland\">Switzerland<\/option><option value=\"Taiwan\">Taiwan<\/option><option value=\"Thailand\">Thailand<\/option><option value=\"Turkey (T\u00fcrkiye)\">Turkey (T\u00fcrkiye)<\/option><option value=\"United Kingdom\">United Kingdom<\/option><option value=\"United States\">United States<\/option><option value=\"Uruguay\">Uruguay<\/option><\/select><\/p><p class=\"aa-trial-filters__field\"><label class=\"aa-trial-filters__label\" for=\"aa-trial-t_kind\">Type d\u2019\u00e9tude<\/label><select class=\"aa-trial-filters__select\" id=\"aa-trial-t_kind\" name=\"t_kind\"><option value=\"\">Toutes les \u00e9tudes<\/option><option value=\"INTERVENTIONAL\">Interventionnelle (traitement)<\/option><option value=\"OBSERVATIONAL\">Observationnelle (registre, imagerie)<\/option><\/select><\/p><p class=\"aa-trial-filters__field\"><label class=\"aa-trial-filters__label\" for=\"aa-trial-t_status\">Statut<\/label><select class=\"aa-trial-filters__select\" id=\"aa-trial-t_status\" name=\"t_status\"><option value=\"\">Tous les statuts<\/option><option value=\"RECRUITING\">Recrute<\/option><option value=\"NOT_YET_RECRUITING\">Pas encore ouverte<\/option><option value=\"ENROLLING_BY_INVITATION\">Sur invitation<\/option><\/select><\/p><p class=\"aa-trial-filters__actions\"><button type=\"submit\" class=\"aa-trial-filters__submit\">Filtrer<\/button><a class=\"aa-trial-filters__reset\" href=\"https:\/\/www.amyloidosisalliance.org\/fr\/\" hidden>Effacer les filtres<\/a><\/p><\/form><div class=\"aa-trial-results\" aria-live=\"polite\" aria-busy=\"false\"><p class=\"aa-trial-count\">Affichage de 1 \u00e0 12 sur 208 essais<\/p><div class=\"aa-trial-grid\"><article class=\"aa-trial-card\"><p class=\"aa-trial-card__flags\"><span class=\"aa-trial-status aa-trial-status--recruiting\">Recrute<\/span><span class=\"aa-trial-type\">ATTR (transthyr\u00e9tine)<\/span><\/p><h3 class=\"aa-trial-card__title\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07358078\" target=\"_blank\" rel=\"noopener noreferrer\">DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting<span class=\"screen-reader-text\"> (s\u2019ouvre sur ClinicalTrials.gov)<\/span><\/a><\/h3><p class=\"aa-trial-card__summary\">The purpose of this study is to: * Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran\u2026<\/p><dl class=\"aa-trial-card__facts\"><div><dt>\u00c9tude<\/dt><dd>Observationnelle (registre, imagerie)<\/dd><\/div><div><dt>Promoteur<\/dt><dd>Alnylam Pharmaceuticals<\/dd><\/div><\/dl><p class=\"aa-trial-card__places\"><span class=\"screen-reader-text\">Recrute en : <\/span><span class=\"aa-trial-place\">Germany<\/span><span class=\"aa-trial-place\">Japan<\/span><span class=\"aa-trial-place\">United States<\/span><\/p><p class=\"aa-trial-card__foot\"><span class=\"aa-trial-card__nct\">NCT07358078<\/span><span class=\"aa-trial-card__updated\">Mis \u00e0 jour le 9 octobre 2026<\/span><\/p><\/article><article class=\"aa-trial-card\"><p class=\"aa-trial-card__flags\"><span class=\"aa-trial-status aa-trial-status--recruiting\">Recrute<\/span><span class=\"aa-trial-type\">Non pr\u00e9cis\u00e9<\/span><\/p><h3 class=\"aa-trial-card__title\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07589595\" target=\"_blank\" rel=\"noopener noreferrer\">A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)<span class=\"screen-reader-text\"> (s\u2019ouvre sur ClinicalTrials.gov)<\/span><\/a><\/h3><p class=\"aa-trial-card__summary\">The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay\u2026<\/p><dl class=\"aa-trial-card__facts\"><div><dt>\u00c9tude<\/dt><dd>Interventionnelle (traitement)<\/dd><\/div><div><dt>Phase<\/dt><dd>Phase 2<\/dd><\/div><div><dt>Promoteur<\/dt><dd>Eli Lilly and Company<\/dd><\/div><\/dl><p class=\"aa-trial-card__places\"><span class=\"screen-reader-text\">Recrute en : <\/span><span class=\"aa-trial-place\">Japan<\/span><span class=\"aa-trial-place\">South Korea<\/span><span class=\"aa-trial-place\">Taiwan<\/span><span class=\"aa-trial-place\">United States<\/span><\/p><p class=\"aa-trial-card__foot\"><span class=\"aa-trial-card__nct\">NCT07589595<\/span><span class=\"aa-trial-card__updated\">Mis \u00e0 jour le 8 octobre 2026<\/span><\/p><\/article><article class=\"aa-trial-card\"><p class=\"aa-trial-card__flags\"><span class=\"aa-trial-status aa-trial-status--recruiting\">Recrute<\/span><span class=\"aa-trial-type\">ATTR (transthyr\u00e9tine)<\/span><\/p><h3 class=\"aa-trial-card__title\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07235462\" target=\"_blank\" rel=\"noopener noreferrer\">A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting<span class=\"screen-reader-text\"> (s\u2019ouvre sur ClinicalTrials.gov)<\/span><\/a><\/h3><p class=\"aa-trial-card__summary\">Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a serious and life-threatening condition where a protein called transthyretin (TTR) misfolds and builds up as amyloid fibrils in\u2026<\/p><dl class=\"aa-trial-card__facts\"><div><dt>\u00c9tude<\/dt><dd>Observationnelle (registre, imagerie)<\/dd><\/div><div><dt>Promoteur<\/dt><dd>Bayer<\/dd><\/div><\/dl><p class=\"aa-trial-card__places\"><span class=\"screen-reader-text\">Recrute en : <\/span><span class=\"aa-trial-place\">Austria<\/span><span class=\"aa-trial-place\">Belgium<\/span><span class=\"aa-trial-place\">Croatia<\/span><span class=\"aa-trial-place\">Denmark<\/span><span class=\"aa-trial-place aa-trial-place--more\">+13<\/span><\/p><p class=\"aa-trial-card__foot\"><span class=\"aa-trial-card__nct\">NCT07235462<\/span><span class=\"aa-trial-card__updated\">Mis \u00e0 jour le 8 octobre 2026<\/span><\/p><\/article><article class=\"aa-trial-card\"><p class=\"aa-trial-card__flags\"><span class=\"aa-trial-status aa-trial-status--recruiting\">Recrute<\/span><span class=\"aa-trial-type\">Non pr\u00e9cis\u00e9<\/span><\/p><h3 class=\"aa-trial-card__title\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07494942\" target=\"_blank\" rel=\"noopener noreferrer\">Impact of a Cardiac Rehabilitation Program on Patients With Cardiac Amyloidosis<span class=\"screen-reader-text\"> (s\u2019ouvre sur ClinicalTrials.gov)<\/span><\/a><\/h3><p class=\"aa-trial-card__summary\">The goal of this clinical trial is to learn if a structured cardiac rehabilitation program can help people with cardiac amyloidosis improve their ability\u2026<\/p><dl class=\"aa-trial-card__facts\"><div><dt>\u00c9tude<\/dt><dd>Interventionnelle (traitement)<\/dd><\/div><div><dt>Promoteur<\/dt><dd>University Hospital, Montpellier<\/dd><\/div><\/dl><p class=\"aa-trial-card__places\"><span class=\"screen-reader-text\">Recrute en : <\/span><span class=\"aa-trial-place\">France<\/span><\/p><p class=\"aa-trial-card__foot\"><span class=\"aa-trial-card__nct\">NCT07494942<\/span><span class=\"aa-trial-card__updated\">Mis \u00e0 jour le 8 octobre 2026<\/span><\/p><\/article><article class=\"aa-trial-card\"><p class=\"aa-trial-card__flags\"><span class=\"aa-trial-status aa-trial-status--recruiting\">Recrute<\/span><span class=\"aa-trial-type\">ATTR (transthyr\u00e9tine)<\/span><\/p><h3 class=\"aa-trial-card__title\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05040373\" target=\"_blank\" rel=\"noopener noreferrer\">Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program<span class=\"screen-reader-text\"> (s\u2019ouvre sur ClinicalTrials.gov)<\/span><\/a><\/h3><p class=\"aa-trial-card__summary\">The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal\/neonatal\/infant outcomes in women exposed to patisiran-LNP.<\/p><dl class=\"aa-trial-card__facts\"><div><dt>\u00c9tude<\/dt><dd>Observationnelle (registre, imagerie)<\/dd><\/div><div><dt>Promoteur<\/dt><dd>Alnylam Pharmaceuticals<\/dd><\/div><\/dl><p class=\"aa-trial-card__places\"><span class=\"screen-reader-text\">Recrute en : <\/span><span class=\"aa-trial-place\">France<\/span><span class=\"aa-trial-place\">Germany<\/span><span class=\"aa-trial-place\">Italy<\/span><span class=\"aa-trial-place\">Netherlands<\/span><span class=\"aa-trial-place aa-trial-place--more\">+3<\/span><\/p><p class=\"aa-trial-card__foot\"><span class=\"aa-trial-card__nct\">NCT05040373<\/span><span class=\"aa-trial-card__updated\">Mis \u00e0 jour le 8 octobre 2026<\/span><\/p><\/article><article class=\"aa-trial-card\"><p class=\"aa-trial-card__flags\"><span class=\"aa-trial-status aa-trial-status--recruiting\">Recrute<\/span><span class=\"aa-trial-type\">ATTR (transthyr\u00e9tine)<\/span><\/p><h3 class=\"aa-trial-card__title\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07223203\" target=\"_blank\" rel=\"noopener noreferrer\">TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy<span class=\"screen-reader-text\"> (s\u2019ouvre sur ClinicalTrials.gov)<\/span><\/a><\/h3><p class=\"aa-trial-card__summary\">The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment,\u2026<\/p><dl class=\"aa-trial-card__facts\"><div><dt>\u00c9tude<\/dt><dd>Interventionnelle (traitement)<\/dd><\/div><div><dt>Phase<\/dt><dd>Phase 3<\/dd><\/div><div><dt>Promoteur<\/dt><dd>Alnylam Pharmaceuticals<\/dd><\/div><\/dl><p class=\"aa-trial-card__places\"><span class=\"screen-reader-text\">Recrute en : <\/span><span class=\"aa-trial-place\">Argentina<\/span><span class=\"aa-trial-place\">Australia<\/span><span class=\"aa-trial-place\">Brazil<\/span><span class=\"aa-trial-place\">Canada<\/span><span class=\"aa-trial-place aa-trial-place--more\">+18<\/span><\/p><p class=\"aa-trial-card__foot\"><span class=\"aa-trial-card__nct\">NCT07223203<\/span><span class=\"aa-trial-card__updated\">Mis \u00e0 jour le 8 octobre 2026<\/span><\/p><\/article><article class=\"aa-trial-card\"><p class=\"aa-trial-card__flags\"><span class=\"aa-trial-status aa-trial-status--recruiting\">Recrute<\/span><span class=\"aa-trial-type\">AL (cha\u00eenes l\u00e9g\u00e8res)<\/span><\/p><h3 class=\"aa-trial-card__title\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05898646\" target=\"_blank\" rel=\"noopener noreferrer\">Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial<span class=\"screen-reader-text\"> (s\u2019ouvre sur ClinicalTrials.gov)<\/span><\/a><\/h3><p class=\"aa-trial-card__summary\">This phase II trial compares shorter-duration versus longer-duration maintenance therapy with daratumumab for improving survival in patients who have received initial treatment with daratumumab\u2026<\/p><dl class=\"aa-trial-card__facts\"><div><dt>\u00c9tude<\/dt><dd>Interventionnelle (traitement)<\/dd><\/div><div><dt>Phase<\/dt><dd>Phase 2<\/dd><\/div><div><dt>Promoteur<\/dt><dd>Mayo Clinic<\/dd><\/div><\/dl><p class=\"aa-trial-card__places\"><span class=\"screen-reader-text\">Recrute en : <\/span><span class=\"aa-trial-place\">United States<\/span><\/p><p class=\"aa-trial-card__foot\"><span class=\"aa-trial-card__nct\">NCT05898646<\/span><span class=\"aa-trial-card__updated\">Mis \u00e0 jour le 1 octobre 2026<\/span><\/p><\/article><article class=\"aa-trial-card\"><p class=\"aa-trial-card__flags\"><span class=\"aa-trial-status aa-trial-status--recruiting\">Recrute<\/span><span class=\"aa-trial-type\">Angiopathie amylo\u00efde c\u00e9r\u00e9brale<\/span><\/p><h3 class=\"aa-trial-card__title\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07250035\" target=\"_blank\" rel=\"noopener noreferrer\">Jiedu Huayu Oral Prescription in the Treatment of Intracranial Hemorrhage Associated With Cerebral Amyloid Angiopathy<span class=\"screen-reader-text\"> (s\u2019ouvre sur ClinicalTrials.gov)<\/span><\/a><\/h3><p class=\"aa-trial-card__summary\">Cerebral hemorrhage, as a serious cerebrovascular disease, has the highest disability rate and mortality rate among all types of cerebrovascular diseases .It has brought\u2026<\/p><dl class=\"aa-trial-card__facts\"><div><dt>\u00c9tude<\/dt><dd>Interventionnelle (traitement)<\/dd><\/div><div><dt>Phase<\/dt><dd>Phase 3<\/dd><\/div><div><dt>Promoteur<\/dt><dd>Beijing Tiantan Hospital<\/dd><\/div><\/dl><p class=\"aa-trial-card__places\"><span class=\"screen-reader-text\">Recrute en : <\/span><span class=\"aa-trial-place\">China<\/span><\/p><p class=\"aa-trial-card__foot\"><span class=\"aa-trial-card__nct\">NCT07250035<\/span><span class=\"aa-trial-card__updated\">Mis \u00e0 jour le 30 septembre 2026<\/span><\/p><\/article><article class=\"aa-trial-card\"><p class=\"aa-trial-card__flags\"><span class=\"aa-trial-status aa-trial-status--recruiting\">Recrute<\/span><span class=\"aa-trial-type\">AL (cha\u00eenes l\u00e9g\u00e8res)<\/span><\/p><h3 class=\"aa-trial-card__title\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07850284\" target=\"_blank\" rel=\"noopener noreferrer\">SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders<span class=\"screen-reader-text\"> (s\u2019ouvre sur ClinicalTrials.gov)<\/span><\/a><\/h3><p class=\"aa-trial-card__summary\">This study evaluates whether daily SMS-based (text messages) symptom monitoring is feasible and acceptable in patients who are undergoing treatment for multiple myeloma (MM)\u2026<\/p><dl class=\"aa-trial-card__facts\"><div><dt>\u00c9tude<\/dt><dd>Observationnelle (registre, imagerie)<\/dd><\/div><div><dt>Promoteur<\/dt><dd>Mayo Clinic<\/dd><\/div><\/dl><p class=\"aa-trial-card__places\"><span class=\"screen-reader-text\">Recrute en : <\/span><span class=\"aa-trial-place\">United States<\/span><\/p><p class=\"aa-trial-card__foot\"><span class=\"aa-trial-card__nct\">NCT07850284<\/span><span class=\"aa-trial-card__updated\">Mis \u00e0 jour le 30 septembre 2026<\/span><\/p><\/article><article class=\"aa-trial-card\"><p class=\"aa-trial-card__flags\"><span class=\"aa-trial-status aa-trial-status--recruiting\">Recrute<\/span><span class=\"aa-trial-type\">Non pr\u00e9cis\u00e9<\/span><\/p><h3 class=\"aa-trial-card__title\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07285044\" target=\"_blank\" rel=\"noopener noreferrer\">The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas<span class=\"screen-reader-text\"> (s\u2019ouvre sur ClinicalTrials.gov)<\/span><\/a><\/h3><p class=\"aa-trial-card__summary\">This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment\u2026<\/p><dl class=\"aa-trial-card__facts\"><div><dt>\u00c9tude<\/dt><dd>Interventionnelle (traitement)<\/dd><\/div><div><dt>Phase<\/dt><dd>Phase 2<\/dd><\/div><div><dt>Promoteur<\/dt><dd>Mayo Clinic<\/dd><\/div><\/dl><p class=\"aa-trial-card__places\"><span class=\"screen-reader-text\">Recrute en : <\/span><span class=\"aa-trial-place\">United States<\/span><\/p><p class=\"aa-trial-card__foot\"><span class=\"aa-trial-card__nct\">NCT07285044<\/span><span class=\"aa-trial-card__updated\">Mis \u00e0 jour le 30 septembre 2026<\/span><\/p><\/article><article class=\"aa-trial-card\"><p class=\"aa-trial-card__flags\"><span class=\"aa-trial-status aa-trial-status--recruiting\">Recrute<\/span><span class=\"aa-trial-type\">AL (cha\u00eenes l\u00e9g\u00e8res)<\/span><\/p><h3 class=\"aa-trial-card__title\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05652335\" target=\"_blank\" rel=\"noopener noreferrer\">A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis<span class=\"screen-reader-text\"> (s\u2019ouvre sur ClinicalTrials.gov)<\/span><\/a><\/h3><p class=\"aa-trial-card__summary\">The primary purpose of this study is to identify the recommended phase 2 dose (RP2D[s]) and schedule(s) to be safe for JNJ-79635322 in Part\u2026<\/p><dl class=\"aa-trial-card__facts\"><div><dt>\u00c9tude<\/dt><dd>Interventionnelle (traitement)<\/dd><\/div><div><dt>Phase<\/dt><dd>Phase 1<\/dd><\/div><div><dt>Promoteur<\/dt><dd>Janssen Research &amp; Development, LLC<\/dd><\/div><\/dl><p class=\"aa-trial-card__places\"><span class=\"screen-reader-text\">Recrute en : <\/span><span class=\"aa-trial-place\">Belgium<\/span><span class=\"aa-trial-place\">France<\/span><span class=\"aa-trial-place\">Japan<\/span><span class=\"aa-trial-place\">Netherlands<\/span><span class=\"aa-trial-place aa-trial-place--more\">+3<\/span><\/p><p class=\"aa-trial-card__foot\"><span class=\"aa-trial-card__nct\">NCT05652335<\/span><span class=\"aa-trial-card__updated\">Mis \u00e0 jour le 28 septembre 2026<\/span><\/p><\/article><article class=\"aa-trial-card\"><p class=\"aa-trial-card__flags\"><span class=\"aa-trial-status aa-trial-status--recruiting\">Recrute<\/span><span class=\"aa-trial-type\">AL (cha\u00eenes l\u00e9g\u00e8res)<\/span><\/p><h3 class=\"aa-trial-card__title\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06768489\" target=\"_blank\" rel=\"noopener noreferrer\">A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma<span class=\"screen-reader-text\"> (s\u2019ouvre sur ClinicalTrials.gov)<\/span><\/a><\/h3><p class=\"aa-trial-card__summary\">The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses [RP2Ds]) and\u2026<\/p><dl class=\"aa-trial-card__facts\"><div><dt>\u00c9tude<\/dt><dd>Interventionnelle (traitement)<\/dd><\/div><div><dt>Phase<\/dt><dd>Phase 1<\/dd><\/div><div><dt>Promoteur<\/dt><dd>Janssen Research &amp; Development, LLC<\/dd><\/div><\/dl><p class=\"aa-trial-card__places\"><span class=\"screen-reader-text\">Recrute en : <\/span><span class=\"aa-trial-place\">Australia<\/span><span class=\"aa-trial-place\">Israel<\/span><span class=\"aa-trial-place\">Netherlands<\/span><span class=\"aa-trial-place\">Spain<\/span><span class=\"aa-trial-place aa-trial-place--more\">+1<\/span><\/p><p class=\"aa-trial-card__foot\"><span class=\"aa-trial-card__nct\">NCT06768489<\/span><span class=\"aa-trial-card__updated\">Mis \u00e0 jour le 25 septembre 2026<\/span><\/p><\/article><\/div><nav class=\"aa-trial-pager\" aria-label=\"Pages de la liste des essais\"><span aria-current=\"page\" class=\"page-numbers current\">1<\/span><a class=\"page-numbers\" href=\"https:\/\/www.amyloidosisalliance.org\/fr\/?t_page=2\">2<\/a><span class=\"page-numbers dots\">\u2026<\/span><a class=\"page-numbers\" href=\"https:\/\/www.amyloidosisalliance.org\/fr\/?t_page=18\">18<\/a><a class=\"next page-numbers\" href=\"https:\/\/www.amyloidosisalliance.org\/fr\/?t_page=2\">Suivant<\/a><\/nav><div class=\"aa-trial-registry\"><p class=\"aa-trial-registry__text\">Cette liste ne couvre que les \u00e9tudes sur l\u2019amylose ouvertes ou sur le point d\u2019ouvrir. Le registre recense toutes les \u00e9tudes, y compris celles d\u00e9j\u00e0 termin\u00e9es.<\/p><div class=\"wp-block-button aa-btn aa-btn--teal\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/clinicaltrials.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">Rechercher toutes les \u00e9tudes sur ClinicalTrials.gov<span class=\"screen-reader-text\"> (s\u2019ouvre dans un nouvel onglet)<\/span><\/a><\/div><\/div><p class=\"aa-trial-source\">Source : ClinicalTrials.gov (U.S. National Library of Medicine). Liste r\u00e9cup\u00e9r\u00e9e pour la derni\u00e8re fois le 9 octobre 2026. <a href=\"https:\/\/clinicaltrials.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">clinicaltrials.gov<\/a><\/p><\/div><\/div><\/div>\n<\/section>\n\n<section class=\"wp-block-group aa-section aa-section--forest aa-cta is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group aa-inner aa-narrow aa-text-center is-layout-flow wp-block-group-is-layout-flow\">\n<h2 class=\"wp-block-heading\">Vous ne savez pas par o\u00f9 commencer\u202f?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Nos associations membres connaissent les \u00e9quipes qui m\u00e8nent ces \u00e9tudes dans leur pays et peuvent vous aider \u00e0 pr\u00e9parer l\u2019\u00e9change avec votre m\u00e9decin.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-aec23bef wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button aa-btn aa-btn--primary\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.amyloidosisalliance.org\/fr\/membres\/\">Trouver une association pr\u00e8s de chez vous<\/a><\/div>\n\n\n\n<div class=\"wp-block-button aa-btn aa-btn--ghost-paper\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.amyloidosisalliance.org\/fr\/nous-contacter\/\">Contacter l\u2019Alliance<\/a><\/div>\n<\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>Accueil\u203aEssais cliniques Recherche Essais cliniques Toutes les \u00e9tudes sur l\u2019amylose qui recrutent, vont ouvrir ou recrutent sur invitation, partout dans le monde, directement issues de ClinicalTrials.gov et mises \u00e0 jour chaque jour. Une information, pas un avis m\u00e9dical. L\u2019Alliance ne conduit pas ces \u00e9tudes et ne peut pas vous y inscrire. Si un essai vous [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1488","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Essais cliniques sur l\u2019amylose qui recrutent dans le monde<\/title>\n<meta name=\"description\" content=\"Toutes les \u00e9tudes sur l\u2019amylose qui recrutent ou vont ouvrir, issues de ClinicalTrials.gov et mises \u00e0 jour chaque jour. Filtrez par type, pays et statut.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.amyloidosisalliance.org\/fr\/essais-cliniques\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Essais cliniques sur l\u2019amylose qui recrutent dans le monde\" \/>\n<meta property=\"og:description\" content=\"Toutes les \u00e9tudes sur l\u2019amylose qui recrutent ou vont ouvrir, issues de ClinicalTrials.gov et mises \u00e0 jour chaque jour. Filtrez par type, pays et statut.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.amyloidosisalliance.org\/fr\/essais-cliniques\/\" \/>\n<meta property=\"og:site_name\" content=\"Amyloidosis Alliance\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/AmyloidosisAlliance\/\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-29T09:06:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1707\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@amyloidosisa\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/fr\\\/essais-cliniques\\\/\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/fr\\\/essais-cliniques\\\/\",\"name\":\"Essais cliniques sur l\u2019amylose qui recrutent dans le monde\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/fr\\\/essais-cliniques\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/fr\\\/essais-cliniques\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766.jpg\",\"datePublished\":\"2026-09-07T14:16:46+00:00\",\"dateModified\":\"2026-09-29T09:06:38+00:00\",\"description\":\"Toutes les \u00e9tudes sur l\u2019amylose qui recrutent ou vont ouvrir, issues de ClinicalTrials.gov et mises \u00e0 jour chaque jour. Filtrez par type, pays et statut.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/fr\\\/essais-cliniques\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.amyloidosisalliance.org\\\/fr\\\/essais-cliniques\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/fr\\\/essais-cliniques\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766.jpg\",\"contentUrl\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/fr\\\/essais-cliniques\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Essais cliniques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/fr\\\/\",\"name\":\"Amyloidosis Alliance\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/fr\\\/#organization\",\"name\":\"Amyloidosis Alliance\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/logo.png\",\"contentUrl\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/logo.png\",\"width\":252,\"height\":252,\"caption\":\"Amyloidosis Alliance\"},\"image\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/AmyloidosisAlliance\\\/\",\"https:\\\/\\\/x.com\\\/amyloidosisa\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Essais cliniques sur l\u2019amylose qui recrutent dans le monde","description":"Toutes les \u00e9tudes sur l\u2019amylose qui recrutent ou vont ouvrir, issues de ClinicalTrials.gov et mises \u00e0 jour chaque jour. Filtrez par type, pays et statut.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.amyloidosisalliance.org\/fr\/essais-cliniques\/","og_locale":"fr_FR","og_type":"article","og_title":"Essais cliniques sur l\u2019amylose qui recrutent dans le monde","og_description":"Toutes les \u00e9tudes sur l\u2019amylose qui recrutent ou vont ouvrir, issues de ClinicalTrials.gov et mises \u00e0 jour chaque jour. Filtrez par type, pays et statut.","og_url":"https:\/\/www.amyloidosisalliance.org\/fr\/essais-cliniques\/","og_site_name":"Amyloidosis Alliance","article_publisher":"https:\/\/www.facebook.com\/AmyloidosisAlliance\/","article_modified_time":"2026-09-29T09:06:38+00:00","og_image":[{"width":1707,"height":1707,"url":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@amyloidosisa","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.amyloidosisalliance.org\/fr\/essais-cliniques\/","url":"https:\/\/www.amyloidosisalliance.org\/fr\/essais-cliniques\/","name":"Essais cliniques sur l\u2019amylose qui recrutent dans le monde","isPartOf":{"@id":"https:\/\/www.amyloidosisalliance.org\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.amyloidosisalliance.org\/fr\/essais-cliniques\/#primaryimage"},"image":{"@id":"https:\/\/www.amyloidosisalliance.org\/fr\/essais-cliniques\/#primaryimage"},"thumbnailUrl":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766.jpg","datePublished":"2026-09-07T14:16:46+00:00","dateModified":"2026-09-29T09:06:38+00:00","description":"Toutes les \u00e9tudes sur l\u2019amylose qui recrutent ou vont ouvrir, issues de ClinicalTrials.gov et mises \u00e0 jour chaque jour. Filtrez par type, pays et statut.","breadcrumb":{"@id":"https:\/\/www.amyloidosisalliance.org\/fr\/essais-cliniques\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.amyloidosisalliance.org\/fr\/essais-cliniques\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.amyloidosisalliance.org\/fr\/essais-cliniques\/#primaryimage","url":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766.jpg","contentUrl":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/hans-reniers-lQGJCMY5qcM-unsplash-scaled-e1788792920766.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.amyloidosisalliance.org\/fr\/essais-cliniques\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.amyloidosisalliance.org\/fr\/"},{"@type":"ListItem","position":2,"name":"Essais cliniques"}]},{"@type":"WebSite","@id":"https:\/\/www.amyloidosisalliance.org\/fr\/#website","url":"https:\/\/www.amyloidosisalliance.org\/fr\/","name":"Amyloidosis Alliance","description":"","publisher":{"@id":"https:\/\/www.amyloidosisalliance.org\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.amyloidosisalliance.org\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.amyloidosisalliance.org\/fr\/#organization","name":"Amyloidosis Alliance","url":"https:\/\/www.amyloidosisalliance.org\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.amyloidosisalliance.org\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/logo.png","contentUrl":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/logo.png","width":252,"height":252,"caption":"Amyloidosis Alliance"},"image":{"@id":"https:\/\/www.amyloidosisalliance.org\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/AmyloidosisAlliance\/","https:\/\/x.com\/amyloidosisa"]}]}},"_links":{"self":[{"href":"https:\/\/www.amyloidosisalliance.org\/fr\/wp-json\/wp\/v2\/pages\/1488","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.amyloidosisalliance.org\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.amyloidosisalliance.org\/fr\/wp-json\/wp\/v2\/types\/page"}],"replies":[{"embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/fr\/wp-json\/wp\/v2\/comments?post=1488"}],"version-history":[{"count":1,"href":"https:\/\/www.amyloidosisalliance.org\/fr\/wp-json\/wp\/v2\/pages\/1488\/revisions"}],"predecessor-version":[{"id":1489,"href":"https:\/\/www.amyloidosisalliance.org\/fr\/wp-json\/wp\/v2\/pages\/1488\/revisions\/1489"}],"wp:attachment":[{"href":"https:\/\/www.amyloidosisalliance.org\/fr\/wp-json\/wp\/v2\/media?parent=1488"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}